The phrase "absorption protein binding" is correct and usable in written English.
It can be used in contexts related to pharmacology or biochemistry, specifically when discussing how drugs interact with proteins in the body.
Example: "The study focused on the absorption protein binding of the new medication to determine its bioavailability."
Alternatives: "drug-protein binding" or "protein absorption binding".
Malnutrition has been associated with changes in drug disposition, including changes in absorption, protein binding, hepatic metabolism and renal elimination.
This could be related to several factors, as an altered drug pharmacokinetic (e.g. modification of absorption, protein binding or distribution, impaired drug metabolism) and a potential for drug interactions with co-medications.
Various PK structural models (i.e., base models) were tested, including different absorption (linear or saturable absorption), protein binding (saturable binding to AAG or the combination of saturable binding to AAG and competitive binding to albumin), and elimination (linear or nonlinear elimination) components.
The current PopPK model was modified by simplifying absorption (first‐order absorption) and protein binding components (saturable binding to AAG only).
Importantly, due to changes in oral absorption, decreased protein binding of drugs, and renal insufficiency with impaired drug clearance, it has been speculated that diabetes might alter the pharmacokinetics of antimicrobial drugs, which could lead to treatment failure or resistance (33).
One might hypothesize that after onset of thyroid disease, changes in the nature of exposure or in the pharmacokinetics of PFOA might occur [including patterns of absorption, distribution (including protein binding) or excretion].
Binding to an unknown target can be influenced by cell absorption and transport, additional protein binding, secondary target interactions, drug metabolism, etc.
Moda et al. [30] developed a database, PK/DB associated with five in silico ADME models to predict human intestinal absorption, human oral bioavailability, plasma protein binding, blood-brain barrier and water solubility.
It has rapid and complete absorption after oral administration, minimal protein binding, minimal hepatic metabolism and is excreted mainly unchanged via the kidneys.
Good oral absorption, metabolic stability, and low protein binding in animals/humans possibly translated into lower in vitro activity of luliconazole despite its higher in vitro activity when compared with flucytosine.
Accompanying calculations of log P and various pharmacokinetic data (human intestinal absorption, blood-brain barrier permeation and protein binding affinities) were performed and correlated with the spectroscopically-derived hydrogen bond accepting abilities.
